All In Biotech

Drug Trial Radar · NCT00447915

Phase II/III Clinical Study of R484iv (Ibandronic Acid) for Primary Osteoporosis

Phase II/III Clinical Study of R484iv (Ibandronic Acid) for Primary Osteoporosis - Comparative Study With Sodium Risedronate Hydrate(RIS) With Vertebral Fracture as an Index -

Last checked: Nov 20, 2026Latest source record: Aug 2, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,265 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,265

Actual

Start

Mar 2007

Primary completion

Aug 2011

Study completion Dec 2011

Sponsor

Lead sponsor
Chugai PharmaceuticalIndustry
Sponsor type
Industry
First posted
Mar 15, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of R484iv by intravenous intermittent administration to patients with primary osteoporosis in comparison with sodium risedronate hydrate (RIS) by oral administration every day. To evaluate also the dose response of R484iv.

Conditions

  • Primary Osteoporosis

Interventions

  • ibandronic acid 0.5mgDrug

    0.5mg(i.v.)/month for 35 months

  • RIS placeboDrug

    0 mg(p.o.)/day for 36 months

  • 1.0mg ibandronic acidDrug

    1.0mg(i.v.)/month for 35 months

  • ibandronic acid placeboDrug

    0mg(i.v.)/month for 35 months

  • 2.5mg RISDrug

    2.5 mg(p.o.)/day for 36 months

  • Calcium and Vitamine D3Dietary supplement

    Calcium 305 mg and Vitamine D3 200IU(p.o.)/day for 36 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of vertebral fractureTime frame: 36 months

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Chubu/Kansai region

    Chubu/Kansai, Japan

  • Chugoku/Kyusyu region

    Chugoku/Kyusyu, Japan

  • Hokkaido/Tohoku region

    Hokkaido/Tohoku, Japan

  • Kanto/Koshinetsu region

    Kanto/Koshinetsu, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.